<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38922299</article-id><article-id pub-id-type="pmc">PMC467092</article-id>
<article-id pub-id-type="publisher-id">2373305</article-id><article-id pub-id-type="doi">10.1080/22221751.2024.2373305</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Early neurosyphilis with serofast state</article-title><alt-title alt-title-type="right-running-head">EMERGING MICROBES &#x00026; INFECTIONS</alt-title><alt-title alt-title-type="left-running-head">S. ZAYET ET AL.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3177-9806</contrib-id><name><surname>Zayet</surname><given-names>Souheil</given-names></name><xref rid="AF1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Poloni</surname><given-names>Samantha</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Gendrin</surname><given-names>Vincent</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Chanal</surname><given-names>Johan</given-names></name><xref rid="AF2" ref-type="aff">b</xref><xref rid="AF3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Dupin</surname><given-names>Nicolas</given-names></name><xref rid="AF2" ref-type="aff">b</xref><xref rid="AF3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Klopfenstein</surname><given-names>Timoth&#x000e9;e</given-names></name><xref rid="AF1" ref-type="aff">a</xref></contrib><aff id="AF1"><label>a</label>Infectious Diseases Department, <institution>Nord Franche-Comt&#x000e9; Hospital</institution>, <city>Trevenans</city>, <country>France</country></aff><aff id="AF2"><label>b</label>Department of Dermatology, <institution>AP-HP, APHP-Cochin Hospital</institution>, <city>Paris</city>, <country>France</country></aff><aff id="AF3"><label>c</label>National Reference Centre for Bacterial Sexually Transmitted Infections, <institution>APHP-Cochin Hospital</institution>, <city>Paris</city>, <country>France</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Souheil Zayet <email xlink:href="souhail.zayet@gmail.com">souhail.zayet@gmail.com</email> Infectious Diseases Department, <institution>Nord Franche-Comt&#x000e9; Hospital</institution>, <city>Trevenans</city>
<postal-code>90400</postal-code>, <country>France</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>6</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>6</month><year>2024</year></pub-date><volume>13</volume><issue>1</issue><elocation-id seq="181">2373305</elocation-id><pub-history><event event-type="received"><date><day>10</day><month>4</month><year>2024</year></date></event><event event-type="revised"><date><day>29</day><month>5</month><year>2024</year></date></event><event event-type="accepted"><date><day>22</day><month>6</month><year>2024</year></date></event><event event-type="tagger"><event-desc>Nova techset</event-desc><date><day>3</day><month>7</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>Converted to JATS 1.2 by Nova Techset</event-desc><date><day>3</day><month>7</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TEMI_13_2373305.pdf"/><abstract><title>ABSTRACT</title><p>We report a rare case of confirmed early neurosyphilis with serofast state in HIV-negative patient, with uncontrolled type 2 diabetes mellitus. Syphilitic meningitis was diagnosed initially on serology and cerebrospinal fluid (CSF) analysis. The patient had persistently raised non-treponemal titres on serum with negative CSF venereal disease research laboratory result, following treatment during 3 years of follow-up.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Neurosyphilis</kwd><kwd>meningitis</kwd><kwd>serofast</kwd><kwd>nontreponemal antibodies</kwd><kwd>cerebrospinal fluid</kwd></kwd-group><support-group><funding-group><funding-statement>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</funding-statement></funding-group></support-group><counts><fig-count count="0"/><table-count count="1"/><equation-count count="0"/><ref-count count="14"/><page-count count="3"/></counts></article-meta></front><body><p>Dear Editor,</p><p>Early and late neurosyphilis differ by duration since symptoms onset, which occurs in patients within one or two years from primary infection in the case of early neurosyphilis [<xref rid="CIT0001" ref-type="bibr">1</xref>]. A variety of neurological symptoms may be observed, such as headaches, cranial nerve palsies, confusion, or meningism. Cerebrospinal fluid (CSF) reveals pleocytosis and mildly elevated protein level concentration but asymptomatic meningitis is the most common presentation [<xref rid="CIT0001" ref-type="bibr">1</xref>].</p><p>Response to treatment is monitored by nontreponemal antibody titre decrease 6&#x02013;12 months after antimicrobial drugs for early neurosyphilis, with serological cure defined as more than a four-fold decline [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Despite clinical recovery from neurosyphilis, some patients continue to have a persistently positive nontreponemal antibody titre without achievement of a four-fold decline at 6&#x02013;12 months; this serological non-response defines a mismatch called &#x0201c;serofast status&#x0201d; [<xref rid="CIT0002" ref-type="bibr">2&#x02013;5</xref>]. This condition has been referred to as &#x0201c;serological failure,&#x0201d; &#x0201c;serological non-response,&#x0201d; &#x0201c;seroresistance,&#x0201d; and &#x0201c;reagin-fast.&#x0201d; The median proportion of patients (in all clinical features of syphilis or stages), who had serological non-response, was 12.1% overall (interquartile range, 4.9&#x02013;25.6) but varied depending on the time points after therapy [<xref rid="CIT0003" ref-type="bibr">3</xref>]. There are few data in the medical literature describing this status in neurosyphilis, with one new case in a recent Turkish cohort of 103 patients living with human immunodeficiency virus (HIV) [<xref rid="CIT0006" ref-type="bibr">6</xref>]. In a Chinese systemic review of 7486 confirmed neurosyphilis cases, only 4% presented a serofast status with CSF serological evidence [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>We report herein a rare case of confirmed early serofast neurosyphilis in HIV-negative patients initially presented with syphilitic meningitis [<xref rid="CIT0001" ref-type="bibr">1</xref>] and diagnosed on serology and CSF analysis.</p><p>A 67-year-old man presented with a three-day history of generalized motor seizures, drowsiness, and became unconscious. He had a past history of hypertension and uncontrolled type 2 diabetes mellitus, with glycated haemoglobin A1c (HbA1c) at 8%. The patient had not sought antibiotics in the weeks prior to admission. On examination, pulse was 76/min regular, blood pressure was 130/80 mmHg, and Glasgow Coma scale was 6/15 (eye opening&#x02009;=&#x02009;4, verbal response&#x02009;=&#x02009;1, and motor response&#x02009;=&#x02009;1). He was afebrile with normal cardiac and pulmonary auscultation. The patient was admitted to the intensive care unit (ICU) for mechanical ventilation.</p><p>Electromyography and brain magnetic resonance imaging (MRI) with angio-MRI sequences were normal. COVID-19 real-time polymerase chain reaction (RT-PCR) on nasopharyngeal was negative. Lumbar puncture (LP) showed clear CSF with elevated white blood cell (WBC) count (16/mm<sup>3</sup>; normal range &#x0003c;5), slightly high total protein level concentration (0.85 g/l; normal range &#x0003c;0.4), and normal CSF glucose concentration (3.6&#x02005;mmol/L; normal range 2.22&#x02013;3.89&#x02005;mmol/L); RT-PCR herpes simplex virus, varicella-zoster virus, <italic toggle="yes">Enterovirus spp</italic>. and <italic toggle="yes">Mycobacterium tuberculosis</italic> and <italic toggle="yes">Toxoplasma gondii</italic> were negative. Serology for Hepatitis B, C and HIV were negative. <italic toggle="yes">Treponema pallidum</italic> serology was positive with reactive nontreponemal (rapid plasma regain-RPR) and treponemal tests (<xref rid="T0001" ref-type="table">Table 1</xref>). A reactive venereal disease research laboratory (VDRL) in CSF was positive. A verified neurosyphilis was diagnosed in our patient according to the 2018 CDC criteria&#x02019;s [<xref rid="CIT0008" ref-type="bibr">8</xref>]. All samples were analyzed at the National Reference Center for sexually transmitted infections (STIs) at Cochin Hospital in Paris [<xref rid="CIT0009" ref-type="bibr">9</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref>]. The patient completely recovered after receiving a daily intravenous infusion of aqueous crystalline penicillin G 20 million units daily for 14 days (as first-line treatment recommended by CDC guidelines) with successful extubation. The patient was also given levetiracetam to control seizures and was discharged from the hospital. One year after, LP follow-up concluded with a normal WBC count with decreased CSF protein concentration (0.74&#x02005;g/L), decreased CSF albumin level (253&#x02005;g/L; normal range &#x0003c;350&#x02005;g/L), and a CSF VDRL negative result. The study of the CSF protein profile by isoelectrofocusing revealed an intrathecal synthesis of total IgG, with a prominent oligoclonal aspect and a high albumin quotient (1.06%; normal range&#x02009;&#x0003c;&#x02009;0.65%). The patient reported that he had no sexual partner or contact. RPR was performed 3, 6, 12, 24, and 36 months after treatment with no declination of titres, which persisted at 16 confirming the serofast state in our patient with no clinical evidence of relapse or affecting any symptoms of hypertension and diabetes afterward during 3 years of follow-up.
<table-wrap position="float" id="T0001"><label>Table 1.</label><caption><p>Serologic test results and CSF analysis in early neurosyphilis patient with seraofast status.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th align="left">&#x000a0;</th><th align="left">Last 2 years*</th><th align="left">At admission</th><th align="left">One-year follow-up</th></tr></thead><tbody><tr><td rowspan="9" align="left">CSF analysis</td><td align="left">WBC count (normal range &#x0003c;5)</td><td align="center">&#x000a0;</td><td align="center">16</td><td align="center">2</td></tr><tr><td align="left">Protein concentration (normal range&#x02009;&#x0003c;&#x02009;0.45&#x02005;g/L)</td><td align="center">&#x000a0;</td><td align="center">0.85</td><td align="center">0.74</td></tr><tr><td align="left">Glucose concentration (normal range: 2.22&#x02013;3.89&#x02005;mmol/L)</td><td align="center">&#x000a0;</td><td align="center">5</td><td align="center">3.7</td></tr><tr><td align="left">qPCR <italic toggle="yes">tpp47/ploA</italic>**</td><td align="center">&#x000a0;</td><td align="center">Negative</td><td align="center">Negative</td></tr><tr><td align="left">VDRL**</td><td align="center">&#x000a0;</td><td align="center">Positive</td><td align="center">Negative</td></tr><tr><td align="left">CSF albumin (mg/L) (normal range &#x0003c;350&#x02005;g/L)</td><td align="center">&#x000a0;</td><td align="center">488</td><td align="center">253</td></tr><tr><td align="left">CSF IgG (normal range:10&#x02013;50&#x02005;mg/L)</td><td align="center">&#x000a0;</td><td align="center">151</td><td align="center">106</td></tr><tr><td align="left">CSF/serum albumin quotient (Q.<sub>alb</sub>) (normal range &#x0003c;0.65%)</td><td align="center">&#x000a0;</td><td align="center">&#x02013;</td><td align="center">1.06</td></tr><tr><td align="left">CSF/serum IgG quotient (Q.<sub>IgG</sub>) (normal range &#x0003c;0.7%)</td><td align="center">&#x000a0;</td><td align="center">&#x02013;</td><td align="center">0.83</td></tr><tr><td rowspan="2" align="left">Serum</td><td align="left">Treponemal test***</td><td align="center">Negative</td><td align="left">Positive (&#x0003e;45)</td><td align="center">&#x02013;</td></tr><tr><td align="left">Nontreponemal test (RPR)****</td><td align="center">Negative</td><td align="center">16</td><td align="center">16</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><bold>Abbreviations</bold>: CSF; cerebrospinal fluid; RT-PCR: real-time polymerase chain reaction; RPR: rapid plasma regain; VDRL: venereal disease research laboratory; and WBC: white blood cell.</p></fn><fn id="TF2"><p>*Previous <italic toggle="yes">Treponema pallidum</italic> serologies were negative in this patient from any time within the last 2 years prior to diagnosis.</p></fn><fn id="TF3"><p>**RT-PCR on QuantStudio&#x02122; 5 Real-Time PCR System (ThermoFisher). polA and Tpp47 genes were amplified in LCS using PCR assays.</p></fn><fn id="TF4"><p>***Using immunoenzymatic assays for the detection of anti-<italic toggle="yes">Treponema pallidum</italic> antibodies.</p></fn><fn id="TF5"><p>****NADAL&#x000ae; VDRL: Agglutination tests providing a qualitative and semi-quantitative determination of plasma regain (antibodies &#x0201c;anti-cardiolipin&#x0201d; (aCL) against some components of damaged tissue from patients infected with <italic toggle="yes">Treponema pallidum</italic>).</p></fn></table-wrap-foot></table-wrap></p><p>In this current report, we describe herein an HIV-negative patient who had persistently raised nontreponemal titres following treatment for severe syphilitic meningitis and stated the importance of not misinterpreting the serofast state.</p><p>Due to the impossible culture in vitro of <italic toggle="yes">T. pallidum</italic> and the poor sensitivity of PCR assay, serological techniques are crucial for the diagnosis and follow-up of syphilitic infections to assess recovery, especially nontreponemal antibodies [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Serofast status is an uncommon serological event in which nontreponemal antibodies persist after treatment. It is more often reported in elderly patients, with female predominance [<xref rid="CIT0002" ref-type="bibr">2</xref>], and immunocompromised patients, especially among people living with HIV [<xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0011" ref-type="bibr">11</xref>], and patients treated before the secondary stage of syphilis [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Ren et al. reported that 84/171 (49%) of patients living with HIV achieved seroreversion with a median (95% confidence interval) time of 2 (1.44, 2.68) years. However, Sena concluded that among 333 HIV-negative patients with early syphilis who demonstrated an initial serological response, only 17.1% had seroreversion at 12 months after therapy [<xref rid="CIT0012" ref-type="bibr">12</xref>].</p><p>After syphilitic infection, treponemal antibodies persist, reflecting the production of specific antibodies by memory B lymphocytes, despite pathogen clearance after treatment [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Nontreponemal antibodies target cardiolipin, which is one of the main mitochondrial membrane components released by tissue damage caused by infection. These antibodies are autoreactive. Down-regulation is, therefore, required and expected after treatment, resulting in a decrease in nontreponemal antibody levels. Thus, serofast status or persisting nontreponemal antibodies after effective therapy may thus represent a failure of immune tolerance rather than a lack of pathogen clearance [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Liu et al. indicate that anti-neurosyphilis therapy can partially change the serofast status in a study comparing asymptomatic neurosyphilis and serofast control patients. However, the cumulative rates of serological cure in the asymptomatic neurosyphilis group were 9.6, 22.1, 25.9, and 30.2% in 3, 6, 9, and 12 months after treatment, which were statistically higher than those of the serofast control group [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Another suggested hypothesis in our patient is that the serofast state may persist due to the uncontrolled type 2 diabetes mellitus. It is known that HbA1c is an indicator of diabetes and neurosyphilis, playing an unclear role in blood&#x02013;brain barrier (BBB) disruption, an essential step in the progression of both diseases [<xref rid="CIT0014" ref-type="bibr">14</xref>].</p><p>In such situations, several studies suggested that there is no impact on serological response after retreatment [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Only a small proportion of patients showed seroreversion after retreatment, without being able to conclude whether this was a delayed effect of the initial treatment or a result of retreatment [<xref rid="CIT0003" ref-type="bibr">3</xref>]. We must be aware of serofast status to correctly inform patients of the absence of contagiousness and not to misinterpret it, given the lack of demonstrated benefit of retreatment.</p></body><back><sec sec-type="COI-statement" disp-level="1" id="S002"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec disp-level="1" id="S003"><title>Ethics statement</title><p>The patient in this manuscript has given written informed consent to the publication of his case details.</p></sec><sec sec-type="data-availability" disp-level="1" id="S004"><title>Data availability statement</title><p>Data are available on request due to privacy restrictions. The data presented in this case study are available on request from the corresponding author.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ropper</surname>
<given-names>AH.</given-names></string-name></person-group>
<article-title>Neurosyphilis</article-title>. <source>N Engl J Med</source>. <year>3 oct 2019</year>;<volume>381</volume>(<issue>14</issue>):<fpage>1358</fpage>&#x02013;<lpage>1363</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1906228</pub-id><pub-id pub-id-type="pmid">31577877</pub-id>
</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tuddenham</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ghanem</surname>
<given-names>KG.</given-names></string-name></person-group>
<article-title>Management of adult syphilis: key questions to inform the 2021 centers for disease control and prevention sexually transmitted infections treatment guidelines</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>13 apr 2022</year>;<volume>74</volume>(<issue>Suppl_2</issue>):<fpage>S127</fpage>&#x02013;<lpage>S133</lpage>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Se&#x000f1;a</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>XH</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy</article-title>. <source>BMC Infect Dis</source>. <year>28 oct 2015</year>;<volume>15</volume>:<fpage>479</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12879-015-1209-0</pub-id><pub-id pub-id-type="pmid">26511465</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Se&#x000f1;a</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Wolff</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Martin</surname>
<given-names>DH</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis</article-title>. <source>Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>d&#x000e9;c 2011</year>;<volume>53</volume>(<issue>11</issue>):<fpage>1092</fpage>&#x02013;<lpage>1099</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cir671</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Papp</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>IU</given-names></string-name>, <string-name><surname>Fakile</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>CDC laboratory recommendations for syphilis testing, United States, 2024</article-title>. <source>MMWR Recomm Rep</source>. <year>8 f&#x000e9;vr 2024</year>;<volume>73</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.rr7301a1</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>K&#x000f6;m&#x000fc;r</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ert&#x000fc;rk</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Sevdimba&#x0015f;</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Evaluation of HIV and syphilis co-infected cases, data from a university hospital</article-title>. <source>Curr HIV Res</source>. <year>16 mai 2024</year>. doi:<pub-id pub-id-type="doi">10.2174/011570162X313718240514042111</pub-id>. Online ahead of print.</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Du</surname>
<given-names>FZ</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>HN</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>JJ</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Neurosyphilis in China: a systematic review of cases from 2009&#x02013;2021</article-title>. <source>Front Med</source>. <year>13 mai 2022</year>;<volume>9</volume>:<fpage>894841</fpage>.</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="other">Syphilis (Treponema pallidum) 2018 case definition | CDC [Internet]; 2022 [cit&#x000e9; 21 d&#x000e9;c 2023]. Disponible sur: <ext-link xlink:href="https://ndc.services.cdc.gov/case-definitions/syphilis-2018/" ext-link-type="uri">https://ndc.services.cdc.gov/case-definitions/syphilis-2018/</ext-link>.</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salle</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mayslich</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Grange</surname>
<given-names>PA</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Specific detection of Treponema pallidum in clinical samples: validation of a qPCR assay combining two genomic targets</article-title>. <source>Sex Transm Infect</source>. <year>mars 2023</year>;<volume>99</volume>(<issue>2</issue>):<fpage>91</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">35459752</pub-id>
</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peeling</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Mabey</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kamb</surname>
<given-names>ML</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Syphilis</article-title>. <source>Nat Rev Dis Primer</source>. <year>12 oct 2017</year>;<volume>3</volume>:<fpage>17073</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrdp.2017.73</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rolfs</surname>
<given-names>RT</given-names></string-name>, <string-name><surname>Joesoef</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Hendershot</surname>
<given-names>EF</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The syphilis and HIV study group</article-title>. <source>N Engl J Med</source>. <year>31 juill 1997</year>;<volume>337</volume>(<issue>5</issue>):<fpage>307</fpage>&#x02013;<lpage>314</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM199707313370504</pub-id><pub-id pub-id-type="pmid">9235493</pub-id>
</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Sena</surname>
<given-names>A.</given-names></string-name></person-group> Seroreversion of nontreponemal antibody titers among HIV-negative patients with an appropriate serological response after treatment of early syphilis. In CDC; 2014 [cit&#x000e9; 29 mai 2024]. Disponible sur: <ext-link xlink:href="https://cdc.confex.com/cdc/std2014/webprogram/Paper34857.html" ext-link-type="uri">https://cdc.confex.com/cdc/std2014/webprogram/Paper34857.html</ext-link>.</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>TW</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Changes of serofast status in HIV negative asymptomatic neurosyphilis patients after treatment</article-title>. <source>Front Med</source>. <year>3 ao&#x000fb;t 2022</year>;<volume>9</volume>:<fpage>938016</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmed.2022.938016</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ge</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Su</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>High HbA1c level is correlated with blood-brain barrier disruption in syphilis patients</article-title>. <source>Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol</source>. <year>janv 2020</year>;<volume>41</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref></ref-list></back></article>